- Home
- CAC vs PLRX Comparison
CAC vs PLRX Comparison
Compare CAC & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAC | PLRX |
|---|---|---|
| Founded | 1875 | 2015 |
| Country | United States | United States |
| Employees | N/A | 49 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.2M | 81.7M |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CAC | PLRX |
|---|---|---|
| Price | $48.14 | $1.34 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $45.50 | $2.67 |
| AVG Volume (30 Days) | 76.0K | ★ 519.3K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.49% | N/A |
| EPS Growth | 6.08 | ★ 29.97 |
| EPS | ★ 3.84 | N/A |
| Revenue | ★ $41,739,000.00 | N/A |
| Revenue This Year | $19.15 | N/A |
| Revenue Next Year | $6.05 | N/A |
| P/E Ratio | $12.55 | ★ N/A |
| Revenue Growth | ★ 16.96 | N/A |
| 52 Week Low | $34.53 | $1.09 |
| 52 Week High | $51.57 | $1.95 |
Technical Indicators
Market Signals| Indicator | CAC | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.27 | 56.09 |
| Support Level | $42.36 | $1.12 |
| Resistance Level | $51.36 | $1.39 |
| Average True Range (ATR) | 1.05 | 0.07 |
| MACD | 0.30 | -0.00 |
| Stochastic Oscillator | 82.43 | 75.47 |
Price Performance
Historical ComparisonAbout CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.